Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):1965–1969. doi: 10.1128/aac.39.9.1965

Bactericidal properties of Campylobacter jejuni-specific immunoglobulin M antibodies in commercial immunoglobulin preparations.

I B Autenrieth 1, A Schwarzkopf 1, J H Ewald 1, H Karch 1, R Lissner 1
PMCID: PMC162864  PMID: 8540699

Abstract

Campylobacter jejuni is one of the most common enterocolitis-causing microorganisms worldwide. It is of particular importance in immunodeficient patients, who frequently are prone to develop extraintestinal manifestations. Since these cases respond poorly to antibiotic treatment, a supportive immunomodulating therapy including the administration of C. jejuni-specific immunoglobulins would be desirable. In the present study, nine commercial immunoglobulin preparations for intravenous use were tested for the presence of C. jejuni lipopolysaccharide (LPS)- and outer membrane protein (OMP)-specific antibodies by using immunoblot and enzyme-linked immunosorbent assay techniques. The immunoglobulin G (IgG) antibody reactivities against these antigens were comparable in eight of nine tested immunoglobulin preparations. Only in one preparation were C. jejuni OMP- and LPS-specific IgM antibodies found. In this preparation the immunoblot test revealed a strong reactivity against both flagellin and a major OMP. Moreover, all immunoglobulin preparations recognized OMPs of C. jejuni serotypes Lior 4, 9, 11, and 29 equally strongly, while the reactivity to an anti-Lior 36 isolate was less marked. Furthermore, the bactericidal properties of three immunoglobulin preparations were tested by means of chemiluminescence signaling in and bacterial killing by human polymorphonuclear leukocytes (PMNL). The results show that the IgM preparation enhanced Campylobacter-triggered chemiluminescence signaling in PMNL as well as killing of C. jejuni by PMNL, while the other immunoglobulin preparations did not do so. These results suggest that the administration of immunoglobulin preparations containing C. jejuni-specific IgM antibodies would be beneficial for patients with severe C. jejuni infections.

Full Text

The Full Text of this article is available as a PDF (449.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguero-Rosenfeld M. E., Yang X. H., Nachamkin I. Infection of adult Syrian hamsters with flagellar variants of Campylobacter jejuni. Infect Immun. 1990 Jul;58(7):2214–2219. doi: 10.1128/iai.58.7.2214-2219.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baqar S., Pacheco N. D., Rollwagen F. M. Modulation of mucosal immunity against Campylobacter jejuni by orally administered cytokines. Antimicrob Agents Chemother. 1993 Dec;37(12):2688–2692. doi: 10.1128/aac.37.12.2688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Black R. E., Levine M. M., Clements M. L., Hughes T. P., Blaser M. J. Experimental Campylobacter jejuni infection in humans. J Infect Dis. 1988 Mar;157(3):472–479. doi: 10.1093/infdis/157.3.472. [DOI] [PubMed] [Google Scholar]
  4. Blaser M. J., Black R. E., Duncan D. J., Amer J. Campylobacter jejuni-specific serum antibodies are elevated in healthy Bangladeshi children. J Clin Microbiol. 1985 Feb;21(2):164–167. doi: 10.1128/jcm.21.2.164-167.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blaser M. J., Duncan D. J., Osterholm M. T., Istre G. R., Wang W. L. Serologic study of two clusters of infection due to Campylobacter jejuni. J Infect Dis. 1983 May;147(5):820–823. doi: 10.1093/infdis/147.5.820. [DOI] [PubMed] [Google Scholar]
  6. Blaser M. J., Perez G. P., Smith P. F., Patton C., Tenover F. C., Lastovica A. J., Wang W. I. Extraintestinal Campylobacter jejuni and Campylobacter coli infections: host factors and strain characteristics. J Infect Dis. 1986 Mar;153(3):552–559. doi: 10.1093/infdis/153.3.552. [DOI] [PubMed] [Google Scholar]
  7. Blaser M. J., Taylor D. N., Feldman R. A. Epidemiology of Campylobacter jejuni infections. Epidemiol Rev. 1983;5:157–176. doi: 10.1093/oxfordjournals.epirev.a036256. [DOI] [PubMed] [Google Scholar]
  8. Borleffs J. C., Schellekens J. F., Brouwer E., Rozenberg-Arska M. Use of an immunoglobulin M containing preparation for treatment of two hypogammaglobulinemic patients with persistent Campylobacter jejuni infection. Eur J Clin Microbiol Infect Dis. 1993 Oct;12(10):772–775. doi: 10.1007/BF02098467. [DOI] [PubMed] [Google Scholar]
  9. Borsos T., Rapp H. J. Complement fixation on cell surfaces by 19S and 7S antibodies. Science. 1965 Oct 22;150(3695):505–506. doi: 10.1126/science.150.3695.505. [DOI] [PubMed] [Google Scholar]
  10. Enders U., Karch H., Toyka K. V., Michels M., Zielasek J., Pette M., Heesemann J., Hartung H. P. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol. 1993 Aug;34(2):136–144. doi: 10.1002/ana.410340208. [DOI] [PubMed] [Google Scholar]
  11. Ewald J. H., Heesemann J., Rüdiger H., Autenrieth I. B. Interaction of polymorphonuclear leukocytes with Yersinia enterocolitica: role of the Yersinia virulence plasmid and modulation by the iron-chelator desferrioxamine B. J Infect Dis. 1994 Jul;170(1):140–150. doi: 10.1093/infdis/170.1.140. [DOI] [PubMed] [Google Scholar]
  12. Fujimoto S., Amako K. Guillain-Barré syndrome and Campylobacter jejuni infection. Lancet. 1990 Jun 2;335(8701):1350–1350. doi: 10.1016/0140-6736(90)91234-2. [DOI] [PubMed] [Google Scholar]
  13. Hammarström V., Smith C. I., Hammarström L. Oral immunoglobulin treatment in Campylobacter jejuni enteritis. Lancet. 1993 Apr 17;341(8851):1036–1036. [PubMed] [Google Scholar]
  14. Kerstens P. J., Endtz H. P., Meis J. F., Oyen W. J., Koopman R. J., van den Broek P. J., van der Meer J. W. Erysipelas-like skin lesions associated with Campylobacter jejuni septicemia in patients with hypogammaglobulinemia. Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):842–847. doi: 10.1007/BF01960888. [DOI] [PubMed] [Google Scholar]
  15. Lindblom G. B., Cervantes L. E., Sjögren E., Kaijser B., Ruiz-Palacios G. M. Adherence, enterotoxigenicity, invasiveness and serogroups in Campylobacter jejuni and Campylobacter coli strains from adult humans with acute enterocolitis. APMIS. 1990 Feb;98(2):179–184. [PubMed] [Google Scholar]
  16. Lior H., Woodward D. L., Edgar J. A., Laroche L. J., Gill P. Serotyping of Campylobacter jejuni by slide agglutination based on heat-labile antigenic factors. J Clin Microbiol. 1982 May;15(5):761–768. doi: 10.1128/jcm.15.5.761-768.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Manninen K. I., Prescott J. F., Dohoo I. R. Pathogenicity of Campylobacter jejuni isolates from animals and humans. Infect Immun. 1982 Oct;38(1):46–52. doi: 10.1128/iai.38.1.46-52.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Martin P. M., Mathiot J., Ipero J., Kirimat M., Georges A. J., Georges-Courbot M. C. Immune response to Campylobacter jejuni and Campylobacter coli in a cohort of children from birth to 2 years of age. Infect Immun. 1989 Aug;57(8):2542–2546. doi: 10.1128/iai.57.8.2542-2546.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mathan V. I., Rajan D. P., Klipstein F. A., Engert R. F. Enterotoxigenic Campylobacter jejuni among children in South India. Lancet. 1984 Oct 27;2(8409):981–981. doi: 10.1016/s0140-6736(84)91193-0. [DOI] [PubMed] [Google Scholar]
  20. McCabe W. R., DeMaria A., Jr, Berberich H., Johns M. A. Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. J Infect Dis. 1988 Aug;158(2):291–300. doi: 10.1093/infdis/158.2.291. [DOI] [PubMed] [Google Scholar]
  21. Mills S. D., Bradbury W. C. Human antibody response to outer membrane proteins of Campylobacter jejuni during infection. Infect Immun. 1984 Feb;43(2):739–743. doi: 10.1128/iai.43.2.739-743.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pavlovskis O. R., Rollins D. M., Haberberger R. L., Jr, Green A. E., Habash L., Strocko S., Walker R. I. Significance of flagella in colonization resistance of rabbits immunized with Campylobacter spp. Infect Immun. 1991 Jul;59(7):2259–2264. doi: 10.1128/iai.59.7.2259-2264.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Penner J. L., Hennessy J. N. Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens. J Clin Microbiol. 1980 Dec;12(6):732–737. doi: 10.1128/jcm.12.6.732-737.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Power M. E., Alm R. A., Trust T. J. Biochemical and antigenic properties of the Campylobacter flagellar hook protein. J Bacteriol. 1992 Jun;174(12):3874–3883. doi: 10.1128/jb.174.12.3874-3883.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sjögren E., Kaijser B., Werner M. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli isolated in Sweden: a 10-year follow-up report. Antimicrob Agents Chemother. 1992 Dec;36(12):2847–2849. doi: 10.1128/aac.36.12.2847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Speed B. R., Kaldor J., Watson J., Newton-John H., Tee W., Noonan D., Dwyer B. W. Campylobacter jejuni/Campylobacter coli-associated Guillain-Barré syndrome. Immunoblot confirmation of the serological response. Med J Aust. 1987 Jul 6;147(1):13–16. doi: 10.5694/j.1326-5377.1987.tb133228.x. [DOI] [PubMed] [Google Scholar]
  27. Vogel U., Autenrieth I. B., Berner R., Heesemann J. Role of plasmid-encoded antigens of Yersinia enterocolitica in humoral immunity against secondary Y. enterocolitica infection in mice. Microb Pathog. 1993 Jul;15(1):23–36. doi: 10.1006/mpat.1993.1054. [DOI] [PubMed] [Google Scholar]
  28. Wokatsch R., Bockemühl J. Serovars and biovars of Campylobacter strains isolated from humans and slaughterhouse animals in northern Germany. J Appl Bacteriol. 1988 Feb;64(2):135–140. doi: 10.1111/j.1365-2672.1988.tb02732.x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES